Pfizer bristles at calls for trial transparency; Targacept vet takes the helm at Faraday;

@FierceBiotech: The 2015 Fierce 15 will be announced in a few weeks. Celebrate the winners with us in October at #BIF15. More | Follow @FierceBiotech

@JohnCFierce: Looking forward to an upcoming panel discussion on organ-on-a-chip tech. And you can't beat the price. More | Follow @JohnCFierce

@DamianFierce: Look at this idiot thing I wrote last year. Article | Follow @DamianFierce

> Novartis ($NVS) has launched the U.S.'s first biosimilar, marketing a copy of Amgen's ($AMGN) Neupogen at a 15% discount after months of legal wrangling. More

> Former Targacept CEO Stephen Hill has taken the top spot at Faraday Pharmaceuticals, a biotech upstart developing treatments for critical care. More

> Pfizer ($PFE) is pushing back against investors calling for the company to release full trial results from past studies, arguing that doing so would provide little benefit to patients. Story

Medical Device News

@FierceMedDev: Updated w/ company comment: Merck, Daktari collaborating on hep C diagnostic. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: HeartWare looks diversify into mitral valve repair with $929M purchase of Valtech Cardio. Article | Follow @VarunSaxena2

@EmilyWFierce: European pharma lobby says 'non' to French funding for off-label Avastin. ICYMI fron FiercePharma | Follow @EmilyWFierce

> Stratasys launches 3-D printer for production of dental devices. Story

> Valeant to buy microsurgery tools company Synergetics for up to $190M. Article

Pharma News

@FiercePharma: China's Ascletis gets Taiwan nod for PhII trial of interferon-free HCV candidate. FiercePharmaAsia article | Follow @FiercePharma

@CarlyHFierce: ICYMI: AstraZeneca sales team revving up for new Brilinta marketing push. More | Follow @CarlyHFierce

> Novartis' LCZ696 scores another victory with early-access blessing in U.K. More

> UCB hands off U.S. generics business to Lannett for $1.23B. Story

Vaccines News

> Daiichi Sankyo inks deal to market AstraZeneca's FluMist in Japan. More

> Cornell grad looks to change the way parents remember vaccine schedules. Report

> GlaxoSmithKline signs on LimmaTech for vaccine R&D. Story

> NHS meningitis B vaccination scheme begins in U.K. Item

> BiondVax pairs with NIAID to test universal flu vaccine in U.S. PhII. Article

CRO News

> PPD partners up to better track trial events. News

> WuXi looks to Japan for manufacturing growth. Report

> BioClinica opens an app umbrella to unite researchers. More

> Chinese drugmaker trades $200M for CDMO Cytovance. Story

> AMRI signs on to help Saneca develop opium-based drugs. Article

Pharma Manufacturing News

> Sun gets direct line to poppy production with buyout of GSK opiates biz. Report

> Lannett manufacturing capacity balloons to 522,000 sq. ft. in short order. Story

> China poaches Indian scientists to build formulation expertise. News

> Novo building huge warehouse to support production expansion. Item

> Sun recalls yet another med made at troubled Halol plant. Report

Pharma Asia News

> Pharma market bets on ASEAN in focus ahead of economic pact. Story

> HK's Medisun, Belgium's Celyad revise C-Cure pact for Greater China. Item

> China's Ascletis gets Taiwan nod for PhII trial of interferon-free HCV candidate. Report

> GSK hep B supplies to Japan hit by Tianjin explosion. Story

> Abbott touts Japan drug-eluting Absorb stent trial results, but no approval timeline. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.